Expanded Pipeline Post-merger with Clywedog Therapeutics, Barinthus Biotherapeutics now sits as part of a larger combined entity, potentially broadening access to additional channels, partners, and co-development opportunities that align with their four platform technologies and five product candidates.

Clinical-Stage Focus As a clinical-stage biopharma with a pipeline spanning infectious disease, autoimmunity, and cancer, there are collaboration and licensing opportunities with larger pharma seeking late-stage or risk-sharing development deals, especially for immunotherapy programs like VTP-300, VTP-1000, and VTP-850.

Platform Advantage Four proprietary platforms (ChAdOx, MVA, SNAP-TI, SNAP-CI) provide multiple collaboration angles—co-development, joint research, or access-to-technology deals—that can be leveraged to accelerate external partnerships and milestone-driven revenue.

Investor & Partners Outreach Recent investor-focused events and leadership promotions signal maturity and visibility; target strategic investors and pharma licensing teams actively seeking innovative T cell immunotherapies to expand their immuno-oncology or infectious disease portfolios.

Global Market Readiness With a global-scale industry landscape and a $216M funding base, Barinthus is positioned to pursue global clinical collaborations, regional licensing, and joint ventures to advance flagship candidates like VTP-1000 for celiac disease, while expanding into adjacent immunotherapy indications.